DK166966B1 - Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater - Google Patents

Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater Download PDF

Info

Publication number
DK166966B1
DK166966B1 DK121683A DK121683A DK166966B1 DK 166966 B1 DK166966 B1 DK 166966B1 DK 121683 A DK121683 A DK 121683A DK 121683 A DK121683 A DK 121683A DK 166966 B1 DK166966 B1 DK 166966B1
Authority
DK
Denmark
Prior art keywords
antibody
cells
group
protein
immunotoxin
Prior art date
Application number
DK121683A
Other languages
Danish (da)
English (en)
Other versions
DK121683D0 (da
DK121683A (da
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9272107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK166966(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DK121683D0 publication Critical patent/DK121683D0/da
Publication of DK121683A publication Critical patent/DK121683A/da
Application granted granted Critical
Publication of DK166966B1 publication Critical patent/DK166966B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK121683A 1982-03-17 1983-03-16 Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater DK166966B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8204547A FR2523445A1 (fr) 1982-03-17 1982-03-17 Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
FR8204547 1982-03-17

Publications (3)

Publication Number Publication Date
DK121683D0 DK121683D0 (da) 1983-03-16
DK121683A DK121683A (da) 1983-09-18
DK166966B1 true DK166966B1 (da) 1993-08-09

Family

ID=9272107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK121683A DK166966B1 (da) 1982-03-17 1983-03-16 Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater

Country Status (27)

Country Link
US (1) US4762707A (fi)
EP (1) EP0089880B1 (fi)
JP (1) JPH0653677B2 (fi)
KR (1) KR910000029B1 (fi)
AT (1) ATE27915T1 (fi)
AU (1) AU563356B2 (fi)
CA (1) CA1216791A (fi)
CS (1) CS268656B2 (fi)
DD (1) DD209578A5 (fi)
DE (1) DE3372175D1 (fi)
DK (1) DK166966B1 (fi)
EG (1) EG15882A (fi)
ES (1) ES520692A0 (fi)
FI (1) FI830897L (fi)
FR (1) FR2523445A1 (fi)
GR (1) GR77119B (fi)
HU (1) HU189246B (fi)
IE (1) IE54624B1 (fi)
IL (1) IL68106A0 (fi)
MA (1) MA19742A1 (fi)
NO (1) NO166618C (fi)
NZ (1) NZ203586A (fi)
OA (1) OA07388A (fi)
PH (1) PH18890A (fi)
PL (1) PL142316B1 (fi)
PT (1) PT76394B (fi)
ZA (1) ZA831833B (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
DE3612643A1 (de) * 1985-12-05 1987-06-11 Mueller Lierheim Kg Biolog Lab Traegerkoerper, der durch kovalent an seine oberflaeche gebundene antikoerper bioaktiviert ist
EP0252951A4 (en) * 1986-01-06 1988-09-07 Univ Melbourne TECHNETIUM-ANTIBODY CONJUGATES.
US5716990A (en) * 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
FR2624010B1 (fr) * 1987-12-07 1991-07-05 Fabre Pierre Cosmetique Compositions topiques heterogenes a base de microgranules de cafeine et/ou de ses derives, utiles comme amincissant et/ou dans le traitement de la cellulite, ainsi que leur preparation
DE3807904A1 (de) * 1988-03-10 1989-09-21 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
AU5732290A (en) * 1989-06-30 1991-01-17 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
KR100236375B1 (ko) * 1989-12-11 1999-12-15 오트리브 데이비스 더블유 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트
AU595786B3 (en) * 1990-01-10 1990-03-12 Chung Ming Pan Spray head assembly
US5965106A (en) * 1992-03-04 1999-10-12 Perimmune Holdings, Inc. In vivo binding pair pretargeting
CA2107558A1 (en) * 1992-03-04 1993-09-05 Nicholas Pomato In vivo binding pair pretargeting
WO1993023080A1 (en) * 1992-05-13 1993-11-25 The Beth Israel Hospital Association Targeted activated species cytotoxicity
ES2287926T3 (es) * 1992-12-04 2007-12-16 Me Medical Enzymes Ag Glutaminasa manipulada geneticamente y su uso en terapia.
DK75593D0 (fi) * 1993-06-25 1993-06-25 Novo Nordisk As
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
CA2606259A1 (en) * 2005-04-27 2006-11-02 Avici Systems An application specific reconfigurable network processor
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
AU2016210551B2 (en) 2015-01-23 2019-03-07 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
JPS53124682A (en) * 1977-04-08 1978-10-31 Asahi Chem Ind Co Ltd Preparation of complex of enzyme and bioactive substance and its use
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5590858A (en) * 1978-12-29 1980-07-09 Asahi Chem Ind Co Ltd Method of measuring substance
JPS588395B2 (ja) * 1979-08-08 1983-02-15 大日本製薬株式会社 マレイミド安息香酸誘導体の製法
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique

Also Published As

Publication number Publication date
AU1250483A (en) 1983-09-22
DE3372175D1 (en) 1987-07-30
IE54624B1 (en) 1989-12-20
MA19742A1 (fr) 1983-10-01
ZA831833B (en) 1983-11-30
AU563356B2 (en) 1987-07-09
DK121683D0 (da) 1983-03-16
PT76394B (fr) 1985-12-05
KR840003815A (ko) 1984-10-04
FI830897A0 (fi) 1983-03-17
FI830897L (fi) 1983-09-18
NO166618C (no) 1991-08-21
DK121683A (da) 1983-09-18
IE830531L (en) 1983-09-17
JPS58208238A (ja) 1983-12-03
PL241047A1 (en) 1983-10-10
PH18890A (en) 1985-10-25
EP0089880A1 (fr) 1983-09-28
EG15882A (en) 1986-09-30
NO166618B (no) 1991-05-13
ES8405071A1 (es) 1984-05-16
EP0089880B1 (fr) 1987-06-24
FR2523445A1 (fr) 1983-09-23
ES520692A0 (es) 1984-05-16
NO830935L (no) 1983-09-19
HU189246B (en) 1986-06-30
CA1216791A (en) 1987-01-20
CS268656B2 (en) 1990-04-11
KR910000029B1 (ko) 1991-01-19
US4762707A (en) 1988-08-09
OA07388A (fr) 1984-11-30
IL68106A0 (en) 1983-06-15
PT76394A (fr) 1983-04-01
ATE27915T1 (de) 1987-07-15
DD209578A5 (de) 1984-05-16
NZ203586A (en) 1986-08-08
FR2523445B1 (fi) 1985-01-11
PL142316B1 (en) 1987-10-31
CS173783A2 (en) 1989-08-14
JPH0653677B2 (ja) 1994-07-20
GR77119B (fi) 1984-09-07

Similar Documents

Publication Publication Date Title
DK166966B1 (da) Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater
Senter et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates
US5239062A (en) Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
JPS61227532A (ja) 抗体ハイブリツド分子およびその製造方法
Vogel et al. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
US4479940A (en) Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications
AU595173B2 (en) Method and use for site-specific activation of substances
JPH0788310B2 (ja) 抗体結合体
JPS5843926A (ja) 選択性制癌剤
US5395924A (en) Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
WO1984000382A1 (en) Improved protocol for the treatment of graft versus host disease
Tsukada et al. An anti-α-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier
KR20030097604A (ko) 세포의 세포내 구획으로 지질화된 면역글로불린을전달하기 위한 조성물, 지질화된 단백질 및 지질화된 항체
JP3340127B2 (ja) 異常増殖性疾患措置のための抗体接合体
KR0185967B1 (ko) 치료용 약물의 부위 특이적 생체내 활성작용
JPS61122224A (ja) 部位選択性プラスミノ−ゲン活性化因子及びその製造方法
CZ186996A3 (en) Method of selective provocation of methionine insufficiency for malignant cells of mammals
Forrester et al. Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75
US5144009A (en) Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated inophores
US5112607A (en) Potentiation of immunotoxin action by Brefeldin A
Carlson et al. Modification of the allosteric activator site of Escherichia coli ADP-glucose synthetase by trinitrobenzenesulfonate
PT87096B (pt) Processo para a preparacao dum derivado de um enzima fibrinolitico
Soloway et al. Future boronated molecules for neutron capture therapy
FR2610198A1 (fr) Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
JPH0276899A (ja) 双特異性抗体の製造法

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed